Alosetron

This classification denotes a 5-ht3 receptor antagonist with the molecular formula C17H18N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13Z9HTH115, chemically known as 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1h-imidazol-4-yl)methyl)-1h-pyrido(4,3-b)indol-1-one but generally known as alosetron, which bears US NIH Compound Identifier 2099. Alosetron comes in base and hydrochloride forms. European Medicines Agency schedules Alosetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05358MIG. The term ALOSETRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules alosetron in its Anatomical Therapeutic Chemical (ATC) Classification. ALOSETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alosetron under HS 29337900 and SITC 51561. As of Q4 2014, ALOSETRON remains the US FDA Preferred Term for this commodity. Alosetron bears US NLM identifiers UMLS ID C0291772 and NCI Concept Code C73100. SMILES: O=C1N(CCC2N(C3C(C12)CCCC3)C)CC1NC[NH]C1C.